Logo Informatori.Info
Rassegna Stampa

Rassegna Stampa per il settore farmaceutico

In questa pagina potrete trovare articoli relativi al settore farmceutico, come ad esempio informazioni su farmaci, sindacati di categoria, aziende farmaceutiche e molto altro.


apr22CHMP Recommends Skilarence for Psoriasis
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended granting marketing authorization for dimethyl fumarate (DMF; Skilarence , Almirall, SA) for the treatment of psoriasis. "Thanks to its efficacy and safety profile, this new oral...

mar19Novartis heart-failure med Entresto cuts A1c, insulin starts in diabetics: analysis
Novartis has been mining a pivotal study of Entresto, its heart-failure med, for more insights ever since it was first published in 2014. Now, a new analysis shows that Entresto beat an older med at reducing blood sugar levels in heart failure patients with diabetes. By breaking out and analy...

feb17Would Pfizer, Roche or Novartis megamerge with BMS? Rumors say they're crunching numbers now
Last month, a couple of analysts addressed Bristol-Myers Squibb as a takeover target for some rival pharma giant. The gist? The combination of disappointments on its cancer blockbuster Opdivo plus a solid product line-up could well put a bullseye on the company—and its “very logical, very rational”...

feb17Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone
Pfizer Inc. PFE, +0.33% said early Thursday that its Xeljanz drug met its primary endpoint in combination with methotrexate as compared to AbbVie's ABBV, -0.28% blockbuster drug Humira, although it didn't meet the primary endpoint on its own. The results of the phase 3B/4 trial, which...

feb16FDA Approves brodalumab (Siliq) for Psoriasis
The US Food and Drug Administration (FDA) today approved an injectable biologic called brodalumab ( Siliq , Valeant Pharmaceuticals) to treat adults with moderate-to-severe psoriasis, but the approval comes with important yellow flags. The agency ordered a boxed label warning on an obser...

nov28Janssen brings psoriasis therapy guselkumab to the EMA
Janssen has filed its potential new psoriasis therapy guselkumab with the European Medicines Agency, hot on the heels of the drug's submission in the US. Guselkumab is a human monoclonal antibody that targets the protein interleukin (IL)-23, which is known to play a key role in the devel...

nov22Biosimilari, l’Aifa mette in stand by i criteri sull’equivalenza terapeutica
L'Agenzia Italiana del Farmaco comunica la sospensione dell'efficacia della Determinazione Aifa-Dg n. 458 del 31 marzo 2016, concernente “Riforma della Determinazione recante procedura di applicazione dell'articolo 15, comma 11 ter, del decreto legge 6 luglio 2012, n. 95 (disposizioni urgenti per l...

nov17European Studies of Infliximab Biosimilar Reassuring
The success of the infliximab biosimilar in two European studies could increase uptake of the agent in the United States, experts said here at the American College of Rheumatology 2016 Annual Meeting. No red flags were raised in the Norwegian and Danish studies when patients switched from the...

nov16Gsk in cima alla classifica dell’Access to Medicine Index
L'azienda si posiziona al primo posto in aree fondamentali come ricerca e sviluppo, politiche di prezzo, produzione e distribuzione di farmaci e vaccini, donazione di prodotti Buone notizie per Gsk , che per la quinta volta consecutiva si conferma al vertice della classifica dell’ Acces...

nov14J&J, GSK stumble coming out of the gate with mixed PhIII rheumatoid arthritis data for sirukumab
This is a big weekend for the wave of late-stage rheumatoid arthritis drugs lining up for a slice of the multibillion-dollar rheumatoid arthritis market. And J&J and GlaxoSmithKline got things started by spelling out the data in a less-than-stellar matchup against AbbVie’s Humira. Investigato...

set19Golimumab Effective for Early Peripheral Spondyloarthritis
The tumor necrosis factor (TNF) inhibitor golimumab ( Simponi , Janssen Biotech) is effective in the treatment of very early peripheral spondyloarthritis, and safety is similar to that seen in other spondyloarthritis conditions, according to new research.

set19Combo Therapy Slows Progression in Ankylosing Spondylitis
The progression of ankylosing spondylitis can be slowed when tumor necrosis factor (TNF) inhibitors are added to high-dose nonsteroidal anti-inflammatory drugs (NSAIDs), possibly because of a synergistic effect between the two drugs, according to new research.

set13Axial Spondyloarthritis: Updated British Guide on Biologics
An updated guideline by two British medical societies is expected to expand access to biologics for patients with axial spondyloarthritis (axSpA; including ankylosing spondylitis [AS]) and increase prescribing flexibility for clinicians in the National Health Service.

set09Ixekizumab Effective in Phase 3 Psoriatic Arthritis Trial
Phase 3 data from the SPIRIT-P1 study showed the new interleukin 17A (IL-17A) inhibitor ixekizumab to be safe and effective for treating psoriatic arthritis (PsA). The findings put the monoclonal on track to join another IL-17A antibody, secukinumab, as PsA therapy, and further highlight the import...

lug20FDA panel gives cautious nod to Valeant psoriasis drug, despite suicide concerns
An FDA advisory committee recommended that the agency approve Valeant’s brodalumab to treat moderate-to-severe plaque psoriasis. But it also advised that the biopharma implement additional risk-management options for suicidal ideation--which had proved to be a problem in Phase III testing.

Cerca la Notizia
Skip Navigation Links.



Articoli Scientifici



Auto Aziendale

Aziende Farmaceutiche

British Medical Journal

Codice Strada



Dispositivi Medici



Eventi ECM










New England


RSU Aziende


SLF Cobas